Selected tags: systematic review

Getting the data on chemicals is just the beginning

Jennifer McPartland, Ph.D., is a Health Scientist.

Common sense tells us it’s impossible to evaluate the safety of a chemical without any data. We’ve repeatedly highlighted the scarcity of information available on the safety of chemicals found all around us (see for example, here and here).  Much of this problem can be attributed to our broken chemicals law, the Toxic Substances Control Act of 1976 (TSCA).

But even for those chemicals that have been studied, sometimes for decades, like formaldehyde and phthalates, debate persists about what the scientific data tell us about their specific hazards and risks.  Obtaining data on a chemical is clearly a necessary step for its evaluation, but interpreting and drawing conclusions from the data are equally critical steps – and arguably even more complicated and controversial. 

How should we evaluate the quality of data in a study? How should we compare data from one study relative to other studies? How should we handle discordant results across similar studies?  How should we integrate data across different study designs (e.g., a human epidemiological study and a fruit fly study)? These are just a few examples of key questions that must be grappled with when determining the toxicity or risks of a chemical.  And they lie at the heart of the controversy and criticism surrounding chemical assessment programs such as EPA’s Integrated Risk Information System (IRIS). 

Recently, a number of efforts have been made to systematize the process of study evaluation, with the goal of creating a standardized approach for unbiased and objective identification, evaluation, and integration of available data on a chemical.  These approaches go by the name of systematic review

Groups like the National Toxicology Program’s Office of Health Assessment and Translation (OHAT) and the UCSF-led Navigation Guide collaboration have been working to adapt systematic review methodologies from the medical field for application to environmental chemicals.  IRIS has also begun an effort to integrate systematic review into its human health assessments. 

Recently a paper in Environmental Health Perspectives (EHP) by Krauth et al. systematically identified and reviewed tools currently in use to evaluate the quality of toxicology studies conducted in laboratory animals.  The authors found significant variability across the tools; this finding has significant consequences when reviewing the evidence for chemical hazard or risk, as we pointed out in our subsequent commentary (“A Valuable Contribution toward Adopting Systematic Review in Environmental Health,” Dec 2013). 

EDF applauds these and other efforts to adopt systematic review in the evaluation of chemical safety.  Further elaboration of EDF’s perspective on systematic review can be found here

 

Posted in Health Policy, Health Science, Regulation| Also tagged | Comments closed
  • About this blog

    Science, health, and business experts at Environmental Defense Fund comment on chemical and nanotechnology issues of the day.

    Our work: Chemicals

  • Categories

  • Get blog posts by email

    Subscribe via RSS

  • Filter posts by tags

    • aggregate exposure (10)
    • Alternatives assessment (3)
    • American Chemistry Council (ACC) (55)
    • arsenic (3)
    • asthma (3)
    • Australia (1)
    • biomonitoring (9)
    • bipartisan (6)
    • bisphenol A (18)
    • BP Oil Disaster (18)
    • California (1)
    • Canada (7)
    • carbon nanotubes (24)
    • carcinogen (21)
    • Carcinogenic Mutagenic or Toxic for Reproduction (CMR) (12)
    • CDC (6)
    • Chemical Assessment and Management Program (ChAMP) (13)
    • chemical identity (30)
    • chemical testing (1)
    • Chemicals in Commerce Act (3)
    • Chicago Tribune (6)
    • children's safety (23)
    • China (10)
    • computational toxicology (10)
    • Confidential Business Information (CBI) (52)
    • conflict of interest (4)
    • consumer products (48)
    • Consumer Specialty Products Association (CSPA) (4)
    • contamination (4)
    • cumulative exposure (4)
    • data requirements (45)
    • diabetes (4)
    • DNA methylation (4)
    • DuPont (11)
    • endocrine disruption (28)
    • epigenetics (4)
    • exposure and hazard (49)
    • FDA (8)
    • flame retardants (20)
    • formaldehyde (15)
    • front group (13)
    • general interest (22)
    • Globally Harmonized System (GHS) (5)
    • Government Accountability Office (5)
    • hazard (6)
    • High Production Volume (HPV) (22)
    • in vitro (14)
    • in vivo (11)
    • industry tactics (41)
    • informed substitution (1)
    • inhalation (18)
    • IUR/CDR (27)
    • Japan (3)
    • lead (6)
    • markets (1)
    • mercury (4)
    • methylmercury (2)
    • microbiome (3)
    • nanosilver (6)
    • National Academy of Sciences (NAS) (20)
    • National Institute for Occupational Safety and Health (NIOSH) (7)
    • National Institute of Environmental Health Sciences (NIEHS) (5)
    • National Nanotechnology Initiative (NNI) (6)
    • obesity (6)
    • Occupational Safety and Health Administration (OSHA) (3)
    • Office of Information and Regulatory Affairs (OIRA) (4)
    • Office of Management and Budget (OMB) (15)
    • Office of Pollution Prevention and Toxics (OPPT) (3)
    • oil dispersant (18)
    • PBDEs (16)
    • Persistent Bioaccumulative and Toxic (PBT) (22)
    • pesticides (7)
    • phthalates (17)
    • polycyclic aromatic hydrocarbons (PAH) (5)
    • prenatal (6)
    • prioritization (35)
    • risk assessment (69)
    • Safe Chemicals Act (24)
    • Safer Chemicals Healthy Families (33)
    • Significant New Use Rule (SNUR) (19)
    • Small business (1)
    • South Korea (4)
    • styrene (6)
    • Substances of Very High Concern (SVHC) (15)
    • systematic review (1)
    • test rule (16)
    • tributyltin (3)
    • trichloroethylene (TCE) (3)
    • Turkey (3)
    • U.S. states (14)
    • vulnerable populations (1)
    • Walmart (2)
    • worker safety (23)
    • WV chemical spill (11)
  • Archives